DDrare: Database of Drug Development for Rare Diseases

168. エーラス・ダンロス症候群
［臨床試験数：7，薬物数：16（DrugBank：8），標的遺伝子数：9，標的パスウェイ数：54］

Searched query = "Ehlers-Danlos syndrome", "EDS", "cEDS", "hEDS", "clEDS", "vEDS", "kEDS", "aEDS", "dEDS", "DDEDS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 0.9% Sodium Chloride Injection; Bupivacaine; Bupivacaine Injection 0.5%; Celiprolol; Chloride; Control; Device: Kera-X; IRBESARTAN; Irbesartan; Lidocaine; Lidocaine Injection 2%; Mecasermin; Mind-body therapy; Riboflavin; Saline; Sodium chloride

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02597361 (ClinicalTrials.gov)	January 2016	23/10/2015	Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)	Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.	Ehlers-Danlos Syndrome, Vascular Type	Drug: Irbesartan;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	Ministry of Health, France	Completed	18 Years	70 Years	All	61	Phase 3	France
2	EUCTR2015-001065-76-FR (EUCTR)	28/09/2015	08/09/2015	N/A	N/A - ARCADE	MedDRA version: 18.0;Level: PT;Classification code 10014316;Term: Ehlers-Danlos syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders	Trade Name: IRBESARTAN Product Name: IRBESARTAN INN or Proposed INN: irbesartan	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Not Recruiting			Female: yes Male: yes	169	Phase 3	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02597361
(ClinicalTrials.gov)

January 2016

23/10/2015

Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)

Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.

Ehlers-Danlos Syndrome, Vascular Type

Drug: Irbesartan;Drug: Placebo

Assistance Publique - Hôpitaux de Paris

Ministry of Health, France

Completed

18 Years

70 Years

All

Phase 3

France

EUCTR2015-001065-76-FR
(EUCTR)

28/09/2015

08/09/2015

N/A

N/A - ARCADE

MedDRA version: 18.0;Level: PT;Classification code 10014316;Term: Ehlers-Danlos syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders

Trade Name: IRBESARTAN
Product Name: IRBESARTAN
INN or Proposed INN: irbesartan

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)

NULL

Not Recruiting

Female: yes
Male: yes

169

Phase 3

France